Plasma Biomarkers of Inflammation, the Kynurenine Pathway, and Risks of All-Cause, Cancer, and Cardiovascular Disease Mortality

We aimed to evaluate 10 biomarkers related to inflammation and the kynurenine pathway, including neopterin, kynurenine:tryptophan ratio, C-reactive protein, tryptophan, and 6 kynurenines, as potential predictors of all-cause and cause-specific mortality in a general population sample. The study cohort was participants involved in a community-based Norwegian study, the Hordaland Health Study (HUSK). We used Cox proportional hazards models to assess associations of the biomarkers with all-cause mortality and competing-risk models for cause-specific mortality. Of the 7,015 participants, 1,496 deaths were recorded after a median follow-up time of 14 years (1998–2012). Plasma levels of inflammatory markers (neopterin, kynurenine:tryptophan ratio, and C-reactive protein), anthranilic acid, and 3-hydroxykynurenine were positively associated with all-cause mortality, and tryptophan and xanthurenic acid were inversely associated. Multivariate-adjusted hazard ratios for the highest (versus lowest) quartiles of the biomarkers were 1.19–1.60 for positive associations and 0.73–0.87 for negative associations. All of the inflammatory markers and most kynurenines, except kynurenic acid and 3-hydroxyanthranilic acid, were associated with cardiovascular disease (CVD) mortality. In this general population, plasma biomarkers of inflammation and kynurenines were associated with risk of all-cause, cancer, and CVD mortality. Associations were stronger for CVD mortality than for mortality due to cancer or other causes.

[1]  Jeffrey N. Martin,et al.  The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. , 2014, The Journal of infectious diseases.

[2]  S. Vollset,et al.  Interferon-γ–induced inflammatory markers and the risk of cancer: The Hordaland Health Study , 2014, Cancer.

[3]  P. Ueland,et al.  Targeted quantification of C-reactive protein and cystatin c and its variants by immuno-MALDI-MS. , 2014, Analytical chemistry.

[4]  P. Brennan,et al.  Most blood biomarkers related to vitamin status, one-carbon metabolism, and the kynurenine pathway show adequate preanalytical stability and within-person reproducibility to allow assessment of exposure or nutritional status in healthy women and cardiovascular patients. , 2014, The Journal of nutrition.

[5]  J. Pedraza-Chaverri,et al.  Kynurenines with Neuroactive and Redox Properties: Relevance to Aging and Brain Diseases , 2014, Oxidative medicine and cellular longevity.

[6]  D. Mellström,et al.  High-Sensitivity CRP Is an Independent Risk Factor for All Fractures and Vertebral Fractures in Elderly Men: The MrOS Sweden Study , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  Hisashi Adachi,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[8]  W. März,et al.  Neopterin is associated with cardiovascular events and all-cause mortality in renal transplant patients , 2013, Clinical transplantation.

[9]  F. Wolf,et al.  Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers , 2016, Clinical Diabetes.

[10]  E. Elinav,et al.  Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms , 2013, Nature Reviews Cancer.

[11]  G. Sulo,et al.  Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. , 2013, International journal of cardiology.

[12]  P. Ueland,et al.  Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography. , 2013, European heart journal.

[13]  J. Cauley,et al.  C‐Reactive Protein, Bone Strength, and Nine‐Year Fracture Risk: Data From the Study of Women's Health Across the Nation (SWAN) , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  S. Vollset,et al.  A community‐based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study , 2013, Clinical and experimental immunology.

[15]  J. Frostegård Immunity, atherosclerosis and cardiovascular disease , 2013, BMC Medicine.

[16]  P. Ueland,et al.  Mechanistic perspective on the relationship between pyridoxal 5'-phosphate and inflammation. , 2013, Nutrition reviews.

[17]  Ira Tabas,et al.  Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities , 2013, Science.

[18]  J. Toldi,et al.  Kynurenines in the CNS: recent advances and new questions , 2012, Nature Reviews Drug Discovery.

[19]  H. Yoon,et al.  High-Sensitivity C-Reactive Protein Levels and Cancer Mortality , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[20]  G. Hansson,et al.  The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice. , 2012, European heart journal.

[21]  H. Putter,et al.  Competing risks in epidemiology: possibilities and pitfalls. , 2012, International journal of epidemiology.

[22]  T. Stone,et al.  Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection , 2012, The FEBS journal.

[23]  Sunhee C. Lee,et al.  The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1. , 2011, The American journal of pathology.

[24]  M. Herrero,et al.  The Involvement of Neuroinflammation and Kynurenine Pathway in Parkinson's Disease , 2011, Parkinson's disease.

[25]  P. Ueland,et al.  Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. , 2011, The Journal of nutrition.

[26]  P. Ueland,et al.  Systemic Markers of Interferon-&ggr;–Mediated Immune Activation and Long-Term Prognosis in Patients With Stable Coronary Artery Disease , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[27]  B. Nordestgaard,et al.  C-reactive protein and all-cause mortality--the Copenhagen City Heart Study. , 2010, European heart journal.

[28]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[29]  J. Danesh,et al.  C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.

[30]  P. Ueland,et al.  Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. , 2009, Rapid communications in mass spectrometry : RCM.

[31]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[32]  M. Sandhu,et al.  Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis , 2009, Diabetologia.

[33]  G. Guillemin,et al.  Kynurenine Pathway Metabolites in Humans: Disease and Healthy States , 2009, International journal of tryptophan research : IJTR.

[34]  J. Toldi,et al.  Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders , 2007, Journal of the Neurological Sciences.

[35]  G. Leipnitz,et al.  In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain , 2007, Neurochemistry International.

[36]  S. Vollset,et al.  The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. , 2006, The Journal of nutrition.

[37]  N. Anthonisen,et al.  C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease , 2006, Thorax.

[38]  D. Fuchs,et al.  Monitoring tryptophan metabolism in chronic immune activation. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[39]  Peter Libby,et al.  Inflammation and cardiovascular disease mechanisms. , 2006, The American journal of clinical nutrition.

[40]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[41]  Cory M. Robinson,et al.  The Role of IFN-γ and TNF-α-Responsive Regulatory Elements in the Synergistic Induction of Indoleamine Dioxygenase , 2005 .

[42]  J. Satagopan,et al.  A note on competing risks in survival data analysis , 2004, British Journal of Cancer.

[43]  S. Vollset,et al.  Distribution and determinants of serum creatinine in the general population: the Hordaland Health Study , 2004, Scandinavian journal of clinical and laboratory investigation.

[44]  K R Hess,et al.  Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. , 1995, Statistics in medicine.

[45]  L. Pan,et al.  Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[46]  S. Czernichow,et al.  Association of C-Reactive ProteinWith Cardiovascular DiseaseMortality According to Diabetes Status Pooled analyses of 25,979 participants from four U.K. prospective cohort studies , 2011 .

[47]  Cory M. Robinson,et al.  The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[48]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .